| P50 | author | Jean-Charles Piette | Q73305204 |
| | Munther A. Khamashta | Q73418907 |
| | Jill P Buyon | Q80060036 |
| | Cecilia Pisoni | Q100488691 |
| | Peter Izmirly | Q42625795 |
| | Nathalie Costedoat-Chalumeau | Q47262464 |
| P2093 | author name string | Carolina Llanos | |
| | Mimi Y Kim | |
| | Amit Saxena | |
| | Deborah Friedman | |
| P2860 | cites work | The rate of recurrence of isolated congenital heart block: a population-based study | Q73565865 |
| | Incidence and spectrum of neonatal lupus erythematosus: a prospective study of infants born to mothers with anti-Ro autoantibodies | Q73600793 |
| | Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women | Q74384559 |
| | Neonatal lupus erythematosus: results of maternal corticosteroid therapy | Q77853554 |
| | Fetal echocardiographic screening of pregnancies of mothers with anti-Ro and/or anti-La antibodies | Q77894676 |
| | Antimalarial agents: closing the gate on Toll-like receptors? | Q79158393 |
| | Outcome of pregnancies in patients with anti-SSA/Ro antibodies: a study of 165 pregnancies, with special focus on electrocardiographic variations in the children and comparison with a control group | Q80845149 |
| | Prolongation of the atrioventricular conduction in fetuses exposed to maternal anti-Ro/SSA and anti-La/SSB antibodies did not predict progressive heart block. A prospective observational study on the effects of maternal antibodies on 165 fetuses | Q83704882 |
| | Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L) | Q31107094 |
| | Hydroxychloroquine in lupus pregnancy | Q33373145 |
| | Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort | Q33455990 |
| | Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block | Q34058776 |
| | Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies | Q34131724 |
| | Variable selection for propensity score models | Q34803815 |
| | A novel role of endothelin-1 in linking Toll-like receptor 7-mediated inflammation to fibrosis in congenital heart block. | Q35182874 |
| | Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. | Q35501152 |
| | Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial. | Q35546634 |
| | Questions about dexamethasone use for the prevention of anti-SSA related congenital heart block | Q35552060 |
| | Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature | Q36049718 |
| | Ro60-associated single-stranded RNA links inflammation with fetal cardiac fibrosis via ligation of TLRs: a novel pathway to autoimmune-associated heart block. | Q36551073 |
| | Disease-modifying antirheumatic drugs in pregnancy: current status and implications for the future | Q36592626 |
| | Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine | Q36672583 |
| | Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study | Q37315454 |
| | Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review | Q37356697 |
| | Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. | Q37393128 |
| | Glucocorticoids in pregnancy | Q37845887 |
| | Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. | Q41919391 |
| | Failure of intravenous immunoglobulin to prevent congenital heart block: Findings of a multicenter, prospective, observational study | Q41936669 |
| | Retinal degeneration in 2 children following preventive antimalarial treatment of the mother during pregnancy | Q41939291 |
| | Ototoxicity of Chloroquine | Q41939943 |
| | Ineffective therapy, underpowered studies, or merely too little, too late? Risk factors and impact of maternal corticosteroid treatment on outcome in antibody-associated fetal heart block | Q46326060 |
| | Isolated atrioventricular block in the fetus: a retrospective, multinational, multicenter study of 175 patients | Q46326249 |
| | Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry | Q46358042 |
| | Optimal two-stage designs for phase II clinical trials | Q46412217 |
| | Matching using estimated propensity scores: relating theory to practice. | Q52891298 |
| | Development of heart block in children of SSA/SSB-autoantibody-positive women is associated with maternal age and displays a season-of-birth pattern | Q57224350 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| | hydroxychloroquine | Q421094 |
| P304 | page(s) | 76-82 | |
| P577 | publication date | 2012-05-24 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus | |
| P478 | volume | 126 | |